Vaccinex to delist its common stock from Nasdaq to focus on developing lead product

From GlobeNewswire: 2025-03-07 17:15:00

Vaccinex, Inc. has decided to delist its common stock from the Nasdaq Stock Market, with trading suspended since December 18, 2024. They will file a Form 25 with the SEC on or about March 17, 2025 for delisting. This decision follows a notice from the Nasdaq Hearings Panel on December 16, 2024. Vaccinex plans to focus on developing its lead product, pepinemab, for Alzheimer’s disease and cancer treatments through partnerships and financing. Pepinemab blocks SEMA4D, a biological effector believed to trigger damaging inflammation in chronic diseases and prevent immune cell activation in tumors.

Vaccinex, Inc. is pioneering a unique approach to treating neurodegenerative diseases and cancer by inhibiting SEMA4D with its lead drug candidate, pepinemab. The company has global commercial and development rights to pepinemab and is sponsoring studies in collaboration with Merck and Co. and Pfizer. Pepinemab has shown promise in clinical trials for various neurological and cancer indications. The company’s forward-looking statements emphasize the expected benefits of delisting from Nasdaq and ongoing development efforts for their lead product.



Read more at GlobeNewswire: Vaccinex Plans to Delist its Common Stock from The Nasdaq